A-TANGO Project

🔬💊A-TANGO has officially ended – but the G-TAK study continues! Our final newsletter highlights the project's achievements, dissemination activities & new publications: mailchi.mp/1600401b049d... The commitment to advance G-TAK beyond A-TANGO and help #cirrhosis & #ACLF patients remains strong. 💪

📣 A major milestone for the A-TANGO project: The first patient with #ACLF has started treatment in the Phase 2 trial evaluating the investigational #G-TAK combination therapy. A crucial step towards developing new treatment options for this life-threatening condition! 🔗 a-tango.eu/wp-content/u...

Back home from an inspiring & energising #EASLCongress in sunny + hot Barcelona 🌅. These were my personal highlights (sound on 🔊) - what were your‘s? 😎 #Barcelona #EASL2026 #LiverDisease #LiverHealth #ACLF @europeliver.bsky.social @medblab.bsky.social @horizoneu.bsky.social @easlnews.bsky.social

👏 3 more outstanding posters 📣 from the coordinating institute UCL at #EASLCongress 2026 - great job, Supacha & Jinxia! 1️⃣ Ammonia-induced bioenergetic failure via #TLR4🔋 2️⃣ YAQ006 and YAQ005 reduce mortality in #ACLF☠️ 3️⃣ Yaq-001 ameliorates liver injury via gut #microbiome🦠 @rajivjalan.bsky.social

💫 Three outstanding Charité posters at #EASLCongress 2026 in Barcelona - well done, Sina, Joscha & Alex! 1️⃣ Body composition & survival in HRS-AKI 2️⃣ Macrophages & gut barrier failure in alcoholic hepatitis🍷 3️⃣ Thrombin generation🩸in #cirrhosis & #ACLF @easlnews.bsky.social @europeliver.bsky.social

🌍 Which #ACLF score performs best? In 3,370 COSSH cohort patients, the A-TANGO score matched the COSSH-ACLF Score for ACLF diagnosis + short-term #mortality prediction, while other models markedly underestimated ACLF. 👉 Visit Meiqian Hu's poster tomorrow! 🔍 #Poster SAT-476 @rajivjalan.bsky.social

🤩 Great attendance & active discussion at #EASLCongress today! Very insightful & interactive Networking Session on the evolving definition and #RiskStratification of ACLF, highlighting the new #ATANGOscore & the urgent need for international #Harmonisation of #ACLF criteria. @rajivjalan.bsky.social

At today’s J Hep Symposium, Benedikt Hofer (author) & Annalisa Berzigotti (challenger) discussed abstinence-induced #Recompensation in #Alcohol-related #Cirrhosis, chaired by Frank Tacke (Charité). 👉 Sustained abstinence = lower mortality 🍷⛔ #EASLCongress #LiverDisease @jhepatology.bsky.social

🧬 Novel #biomarker composites may help predict #AKI and #mortality following acute decompensation of #cirrhosis. 📍Presented in #POSTER WED-448-YI by Olivia Greenham et al. during #EASLCongress 2026! #RiskStratification #LiverDisease #Patients @europeliver.bsky.social @rajivjalan.bsky.social

🧬 Genetic #Cholestasis in adults: When to test? That's the question A-TANGO consortium member Thomas Berg asked today as chair + speaker in the Ipsen Symposium "Rare Genetic #LiverDiseases - Bridging the Gap from #GeneticTesting to #PatientManagement". #EASL2026 #RareDiseases @easlnews.bsky.social

📢 Full house at the EF CLIF Networking Session today at #EASLCongress here in their local Barcelona 😎 An exciting new initiative is a new #MasterProgramme, starting in Fall 2026🎓 #cirrhosis #ACLF #LiverFailure #EASL2026 @decision4liver.bsky.social @microb-predict.bsky.social @a-tango.bsky.social

🧠 The modified hepatic encephalopathy staging tool (mHEST) outperformed West Haven criteria in diagnostic consistency and prognostic performance. #POSTER TOP-471-YI by Annarein Kerbert et al. #EASL2026 #HepaticEncephalopathy #Cirrhosis #Hepatology @rajivjalan.bsky.social @europeliver.bsky.social

In the co-session 'Patient/provider communication', @korenjak.bsky.social (president of @europeliver.bsky.social) stresses three vital in this communication relationship: ⏳ Time 📍Point-of-view 💬Miscommunication @microb-predict.bsky.social @a-tango.bsky.social #EASL2026 #EASLCongress

📣 SNEAK PEEK 🔍 of posters, talks, networking sessions & chairing activities by Consortium Members during #EASLCongress next week (27-30 May 2026) in Barcelona! #ACLF #cirrhosis #LiverDisease #LiverFailure #Hepatology #LiverSky @rajivjalan.bsky.social @europeliver.bsky.social @easlnews.bsky.social

🥳 Join the A-TANGO Networking Session at #EASLCongress! 🗓 Fri, 29 May 2026 ⏰ 10:00–10:30 📍 Cirrhosis & Complications Track Hub 6 The A-TANGO Score: A Novel Tool for Risk Stratification & #ClinicalEndpoints in #ACLF @rajivjalan.bsky.social @easlnews.bsky.social @europeliver.bsky.social

📣 Join the MICROB-PREDICT Consensus Conference at #EASLCongress next week! 📅 Wed, 27 May | 15:30 – 18:30 h 📍 Jansen Room, Hall 8.0, Fira Gran Via (North Access) 👥 Open to registered EASL attendees 📌 On-site event #Microbiome #Hepatology #Cirrhosis #ACLF @easlnews.bsky.social @medblab.bsky.social

🥳 How are you planning to celebrate #WorldLiverDay? And what do you do to strengthen your own liver? #SolidHabitsStrongLiver 👉 Eat healthy - daily 🥦 👉 Move your body - daily 🥎🎾🏃‍➡️ 👉 Reduce alcohol - always🍷 ➡️ 🥛 (there is no "safe" amount of alcohol) 👉 Get your liver checked regularly by a doctor 🩺

📣 IMAC invites you to an upcoming webinar examining how evidence in rare disease trials can be interpreted more rigorously. 🎓 𝗙𝗿𝗼𝗺 𝗙𝘂𝘁𝗶𝗹𝗶𝘁𝘆 𝘁𝗼 𝗨𝗻𝗱𝗲𝗿𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴: 𝗪𝗵𝗮𝘁 𝗮 𝗕𝗮𝘆𝗲𝘀𝗶𝗮𝗻 𝗟𝗲𝗻𝘀 𝗥𝗲𝘃𝗲𝗮𝗹𝘀 𝗶𝗻 𝗥𝗮𝗿𝗲 𝗗𝗶𝘀𝗲𝗮𝘀𝗲 𝗧𝗿𝗶𝗮𝗹𝘀 📅 April 9 ⏰ 4:00 pm CET 👉 Register here: events.teams.microsoft.com/event/9ed2de...

📣 New publication introducing the A-TANGO Organ Failure (OF) score for improved detection of acute-on-chronic liver failure #ACLF in patients with acute #decompensation of #cirrhosis 👍3,896 patients 👍validated in India & China 👍improves diagnostic accuracy www.sciencedirect.com/science/arti...

🥂 We have good news for the holidays: The technical hold-up in the EU portal has finally been resolved & we submitted the 3rd #PeriodicReport ☺️ Wishing everyone relaxing holidays❄️ Together, we are moving from bench to bedside to bring innovative therapies to #ACLF patients @rajivjalan.bsky.social

As the year draws to a close, we are wrapping up 2025 with gratitude, momentum, and a spirit of community at concentris. ✨ 💡Curious about what’s next in 2026, and how these developments could support your work? Read our latest #newsletter: 🔗 mailchi.mp/concentris/n...

On Wednesday, 26 Nov, at 6 pm CET, EASL Studio hosts a new episode titled “Rifaximin for Hepatic Encephalopathy: Balancing Benefits and Risks in the Era of Antimicrobial Resistance” The episode will be broadcast live on EASL.eu and can be accessed here: 📹 easl.eu/easl-studio-... Don't miss it ☺️

👏 1st Site Visit Completed for A-TANGO's #ClinicalTrial: Thanks to big efforts by Yaqrit + Royal Free Hospital, we have kicked off our Phase 2a trial, evaluating the safety of #TLR4 antagonist in combination with #G-CSF for the treatment of #ACLF! #BenchToBedside #cirrhosis @rajivjalan.bsky.social

For #WorldHepatitisDay we stand together 🩺 At A‑TANGO, we aim to transform healthcare for people with #LiverDisease, including those living with #cirrhosis and #ACLF, putting #patients first ☺️ Every person deserves timely, effective, and #stigma‑free support 💪 @europeliver.bsky.social @who.int

What an inspiring 9th Steering Committee Meeting! It was lovely to meet fellow liver-health enthusiasts & clinical investigators who recently joined the #GTAK Study. Let's include as many #ACLF patients in the study as possible.💉😊 #AlcoholicHepatitis @europeliver.bsky.social @easlnews.bsky.social

Join this exciting event! Don't miss our #OpenInnovation event, uniting experts in #DrugDevelopment, #bioinformatics, and #hepatology. Connect with researchers, industry professionals, and investors to share insights & explore collaboration opportunities! 🚀 Register now: inevent.uk/en/Crowdheli...

At #EASL2025, ELPA President Marko Korenjak presented 3 EU projects: A-TANGO, LIVER AIM & THRIVE. At the Layperson Events, science met real stories — patients at the center of innovation, action & hope. @liveraim.bsky.social @A-TANGO @THRIVE @korenjak.bsky.social @ninadonner.bsky.social

🧠 SAT-210 – #EASL2025 New tool alert! The #mHEST scale brings clarity to grading hepatic #encephalopathy in trials & clinics. A big step for #cirrhosis care. Kudos to Prof. @rajivjalan.bsky.social & his team! #LiverHealth #HE #ClinicalResearch

🧪 SAT-209 – #EASL2025 MNK6106 vs. rifaximin to treat #HepaticEncephalopathy - new Phase 2a data from Prof. @rajivjalan.bsky.social (UCL) explores safety, PK & ammonia-lowering potential. HE treatment innovation in motion! #Cirrhosis

👏 Fantastic job by Annarein Kerbert, LUMC, + Julian Pohl, Charité, at today's #networking session at #EASLCongress 👉 Is #alcohol-related #hepatitis in ACLF its own beast? 👉 Is systemic #inflammation the puppet master pulling #ACLF’s strings in booze-related hepatitis? Chair @rajivjalan.bsky.social

👑 The crown belongs to Julian Pohl for one of this year's TOP #Posters at #EASLCongress - Wow! 👏 🥳 TOP-217-YI 🥳 Pathophysiological basis of #ACLF triggered by #alcohol-related #hepatitis or #infection using circulating biomarkers of #inflammation, circulatory dysfunction & #albumin modifications

Today’s #readoftheweek📚 highlights the presence of inflammation and bacterial products in the systemic circulation in patients with compensated #cirrhosis and clinically significant portal hypertension. Read here this JHEP Reports article: www.jhep-reports.eu/article/S258... #LiverSky

🥳 SATURDAY 🥳 If you didn't party too hard on Friday eve: Step by, say hi and listen to exciting talks by Annarein Kerbert, LUMC & Julian Pohl, Charité #AlcoholicHepatitis #cirrhosis #ACLF #inflammation @rajivjalan.bsky.social @medblab.bsky.social @decision4liver.bsky.social @easlnews.bsky.social

Big crowd at the #ACLF & Critical Illness #PosterTour at #EASLCongress: FRI-197 The AMMON-OHE model predicts #liver-related #complications in #outpatients with #cirrhosis: A prospective cohort study of the #AMMON consortium Crucial for understanding the disease progression! @rajivjalan.bsky.social

🌟 POSTER THU-182 by Supachaya S. (UCL, @rajivjalan.bsky.social) featured in a #PosterTour at #EASLCongress! 👏 👉 Transcriptomic & metabolic insights into #hyperammonemia: The complementary therapeutic roles of #TLR4 inhibitor (#TAK242) + ornithine phenylacetate 👍 In A-TANGO, we use #TAK242 + G-CSF

🎬 Summary #movie of A-TANGO's Investigator & Industry Session 🥂 at #EASLCongress. Big thanks to Yaqrit for sponsoring this inspiring event. Let's roll up our sleeves now to start the #GTAK trial in the UK, and hopefully also in India + Germany & other EU countries 🩺 ☺️! #ACLF #cirrhosis #LiverFailure

💲💰 Wake up your inner #entrepreneur, found your own start-up #company #business, and learn from expert @rajivjalan.bsky.social about how to manage financial conflicts of interest #COI Today at #EASLCongress as part of a #YoungInvestigator Seminar! 📍 Erlinger Room 📅 Thurs, May 8 ⏲️ 15:35 - 15:45 h

📣 Today: #POSTER TOP-203, congrats 🥳 A rising international star is A-TANGO #YoungInvestigator Wenting Tan, UCL 👉 Recombinant insulin-like growth factor-1 #IGF1: a novel therapy for #patients with #cirrhosis + #ACLF 👉 Topic: Cirrhosis & Complications #LiverFailure #ACLF @rajivjalan.bsky.social

📣 Another top-notch #poster at the very heart of A-TANGO is THU-180-YI by Supachaya Sriphoosanaphan, UCL 👉 #TLR4 inhibition restores cytochrome C oxidase mitigating #hyperammonemia-induced hepatocyte mitochondrial dysfunction #Cirrhosis & Complications #ACLF #LiverFailure @rajivjalan.bsky.social

📣 Two fantastic #posters today - visit them before 5 pm! Both by Supachaya Sriphoosanaphan, UCL 👉 THU-182 Transcriptomic and metabolic insights into #hyperammonemia: the complementary therapeutic roles of #TLR4 inhibitor and ornithine phenylacetate 👉 #Cirrhosis & Complications #ACLF #LiverFailure